Furthermore, TP53-specific mutation combinations (HRD-high mutations and HRD common mutations) predict the HRD status of patients, which indicates that TP53 pathogenic mutations may serve as potential biomarkers for PARPi in breast cancer patients. The gene discussed is TP53; the disease is breast carcinoma.